How much should we invest in antibiotics? Investigating their option value

Itamar Megiddo

Abstract

The existing business models for antibiotics fail to promote antibiotics stewardship to preserve our existing portfolio of drugs, while at the same time funding for research and development has been insufficient in recent decades, as only two novel classes of antibiotics have been introduced since the 1970s. The UK is considering novel mechanisms for paying for antibiotics to overcome these issues. We will explore the option value for preserving novel antibiotics for extreme events. We will discuss the option value implications for investment in new antibiotics and possible extensions to the model.

Original language	English
Publication status	Published - 29 Jul 2019
Event	INFORMS Healthcare 2019 - Massachusetts Institute of Technology (MIT), Cambridge, United States Duration: 26 Jul 2019 → 30 Jul 2019 http://meetings2.informs.org/wordpress/healthcare2019/

Conference

Conference	INFORMS Healthcare 2019
Country	United States
City	Cambridge
Period	26/07/19 → 30/07/19
Internet address	http://meetings2.informs.org/wordpress/healthcare2019/

Keywords

healthcare management
antibiotics
drug investment

Fingerprint Dive into the research topics of 'How much should we invest in antibiotics? Investigating their option value'. Together they form a unique fingerprint.

1 Article

Investing in antibiotics to alleviate future catastrophic outcomes: what is the value of having an effective antibiotic to mitigate pandemic influenza?
Megiddo, I., Drabik, D., Bedford, T., Morton, A. D., Wesseler, J. & Laxminarayan, R., 1 Apr 2019, In: Health Economics. 28, 4, p. 556-571 16 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File

9 Citations (Scopus)

5 Downloads (Pure)

2 Invited talk

The option value of antibiotics
Itamar Megiddo (Speaker)
16 May 2019
Activity: Talk or presentation types › Invited talk
The option vlaue of antibiotics (in the context of market pull-mechanisms)
Itamar Megiddo (Speaker)
9 May 2019
Activity: Talk or presentation types › Invited talk

Cite this

@conference{c06ed27ae1054fec9a59690ebc73350e,

title = "How much should we invest in antibiotics? Investigating their option value",

abstract = "The existing business models for antibiotics fail to promote antibiotics stewardship to preserve our existing portfolio of drugs, while at the same time funding for research and development has been insufficient in recent decades, as only two novel classes of antibiotics have been introduced since the 1970s. The UK is considering novel mechanisms for paying for antibiotics to overcome these issues. We will explore the option value for preserving novel antibiotics for extreme events. We will discuss the option value implications for investment in new antibiotics and possible extensions to the model.",

keywords = "healthcare management, antibiotics, drug investment",

author = "Itamar Megiddo",

year = "2019",

month = jul,

day = "29",

language = "English",

note = "INFORMS Healthcare 2019 ; Conference date: 26-07-2019 Through 30-07-2019",

url = "http://meetings2.informs.org/wordpress/healthcare2019/",

}

TY - CONF

T1 - How much should we invest in antibiotics? Investigating their option value

AU - Megiddo, Itamar

PY - 2019/7/29

Y1 - 2019/7/29

N2 - The existing business models for antibiotics fail to promote antibiotics stewardship to preserve our existing portfolio of drugs, while at the same time funding for research and development has been insufficient in recent decades, as only two novel classes of antibiotics have been introduced since the 1970s. The UK is considering novel mechanisms for paying for antibiotics to overcome these issues. We will explore the option value for preserving novel antibiotics for extreme events. We will discuss the option value implications for investment in new antibiotics and possible extensions to the model.

AB - The existing business models for antibiotics fail to promote antibiotics stewardship to preserve our existing portfolio of drugs, while at the same time funding for research and development has been insufficient in recent decades, as only two novel classes of antibiotics have been introduced since the 1970s. The UK is considering novel mechanisms for paying for antibiotics to overcome these issues. We will explore the option value for preserving novel antibiotics for extreme events. We will discuss the option value implications for investment in new antibiotics and possible extensions to the model.

KW - healthcare management

KW - antibiotics

KW - drug investment

M3 - Abstract

T2 - INFORMS Healthcare 2019

Y2 - 26 July 2019 through 30 July 2019

ER -

How much should we invest in antibiotics? Investigating their option value

Abstract

Conference

Keywords

Investing in antibiotics to alleviate future catastrophic outcomes: what is the value of having an effective antibiotic to mitigate pandemic influenza?

The option value of antibiotics

The option vlaue of antibiotics (in the context of market pull-mechanisms)

Cite this